Elpiniki Nikolaou1, Elena Kamilari1, Dragana Savkov1, Artemy Sergeev2, Irina Zakharova3, Paris Vogazianos4, Marios Tomazou4, Athos Antoniades4, Christos Shammas5. 1. Genetics Department, AVVA Pharmaceuticals Ltd, 23A Spyrou Kyprianou, 4001, Limassol, Cyprus. 2. Research and Development, MC Development LLC, Moscow, Russia. 3. Russian Medical Academy of Continuing Professional Education, Moscow, Russia. 4. Stremble Ventures Ltd, Limassol, Cyprus. 5. Genetics Department, AVVA Pharmaceuticals Ltd, 23A Spyrou Kyprianou, 4001, Limassol, Cyprus. c.shammas@avvapharma.com.
Abstract
BACKGROUND: Next-generation sequencing has revolutionized our perspective on the gut microbiome composition, revealing the true extent of the adverse effects of antibiotics. The impact of antibiotic treatment on gut microbiota must be considered and researched to provide grounds for establishing new treatment strategies that are less devastating on commensal bacteria. This study investigates the impact on gut microbiome when a commonly used antibiotic, azithromycin is administered, as well as uncovers the benefits induced when it is used in combination with lactulose, a prebiotic known to enhance the proliferation of commensal microbes. METHODS: 16S rRNA gene sequencing analysis of stool samples obtained from 87 children treated withazithromycin in combination with or without lactulose have been determined. Children's gut microbial profile was established at the pre- and post-treatment stage. RESULTS:Azithromycin caused an increase in the relative abundance of opportunistic pathogens such as Streptococcus that was evident 60 days after treatment. While few days after treatment, children who also received lactulose started to show a higher relative abundance of saccharolytic bacteria such as Lactobacillus, Enterococcus, Anaerostipes, Blautia and Roseburia, providing a protective role against opportunistic pathogens. In addition, azithromycin-prebiotic combination was able to provide a phylogenetic profile more similar to the pre-treatment stage. CONCLUSION: It is suggested that during azithromycin treatment, lactulose is able to reinstate the microbiome equilibrium much faster as it promotes saccharolytic microbes and provides a homeostatic effect that minimizes the opportunistic pathogen colonization.
RCT Entities:
BACKGROUND: Next-generation sequencing has revolutionized our perspective on the gut microbiome composition, revealing the true extent of the adverse effects of antibiotics. The impact of antibiotic treatment on gut microbiota must be considered and researched to provide grounds for establishing new treatment strategies that are less devastating on commensal bacteria. This study investigates the impact on gut microbiome when a commonly used antibiotic, azithromycin is administered, as well as uncovers the benefits induced when it is used in combination with lactulose, a prebiotic known to enhance the proliferation of commensal microbes. METHODS: 16S rRNA gene sequencing analysis of stool samples obtained from 87 children treated with azithromycin in combination with or without lactulose have been determined. Children's gut microbial profile was established at the pre- and post-treatment stage. RESULTS:Azithromycin caused an increase in the relative abundance of opportunistic pathogens such as Streptococcus that was evident 60 days after treatment. While few days after treatment, children who also received lactulose started to show a higher relative abundance of saccharolytic bacteria such as Lactobacillus, Enterococcus, Anaerostipes, Blautia and Roseburia, providing a protective role against opportunistic pathogens. In addition, azithromycin-prebiotic combination was able to provide a phylogenetic profile more similar to the pre-treatment stage. CONCLUSION: It is suggested that during azithromycin treatment, lactulose is able to reinstate the microbiome equilibrium much faster as it promotes saccharolytic microbes and provides a homeostatic effect that minimizes the opportunistic pathogen colonization.
Authors: Nicholas A Bokulich; Jennifer Chung; Thomas Battaglia; Nora Henderson; Melanie Jay; Huilin Li; Arnon D Lieber; Fen Wu; Guillermo I Perez-Perez; Yu Chen; William Schweizer; Xuhui Zheng; Monica Contreras; Maria Gloria Dominguez-Bello; Martin J Blaser Journal: Sci Transl Med Date: 2016-06-15 Impact factor: 17.956
Authors: Paul I Costea; Falk Hildebrand; Manimozhiyan Arumugam; Fredrik Bäckhed; Martin J Blaser; Frederic D Bushman; Willem M de Vos; S Dusko Ehrlich; Claire M Fraser; Masahira Hattori; Curtis Huttenhower; Ian B Jeffery; Dan Knights; James D Lewis; Ruth E Ley; Howard Ochman; Paul W O'Toole; Christopher Quince; David A Relman; Fergus Shanahan; Shinichi Sunagawa; Jun Wang; George M Weinstock; Gary D Wu; Georg Zeller; Liping Zhao; Jeroen Raes; Rob Knight; Peer Bork Journal: Nat Microbiol Date: 2018-03 Impact factor: 30.964
Authors: Cindy Duysburgh; Pieter Van den Abbeele; Dennis Franckenstein; Martin Westphal; Angelika Kuchinka-Koch; Massimo Marzorati Journal: Antibiotics (Basel) Date: 2022-07-18